BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 15585611)

  • 21. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
    Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonmyeloablative transplants: preclinical and clinical results.
    Sandmaier BM; McSweeney P; Yu C; Storb R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):78-81. PubMed ID: 10877058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
    Niederwieser D; Maris M; Shizuru JA; Petersdorf E; Hegenbart U; Sandmaier BM; Maloney DG; Storer B; Lange T; Chauncey T; Deininger M; Pönisch W; Anasetti C; Woolfrey A; Little MT; Blume KG; McSweeney PA; Storb RF
    Blood; 2003 Feb; 101(4):1620-9. PubMed ID: 12393457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
    Loren AW; Luger SM; Stadtmauer EA; Tsai DE; Schuster S; Nasta SD; Goldstein SC; Perl A; Orloff G; Oliver JC; Green J; Emerson SG; Porter DL
    Bone Marrow Transplant; 2005 May; 35(9):921-6. PubMed ID: 15765118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation.
    Kurokawa T; Fischer K; Bertz H; Hoegerle S; Finke J; Mackensen A
    Int J Cancer; 2002 Sep; 101(1):52-60. PubMed ID: 12209588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
    Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
    Nakagawa T; Kami M; Hori A; Kim SW; Murashige N; Hamaki T; Kishi Y; Fujimoto H; Matsuoka N; Okajima E; Komiyama M; Tobisu K; Wakayama T; Uike N; Tajima K; Makimoto A; Mori S; Tanosaki R; Takaue Y; Kakizoe T
    Exp Hematol; 2004 Jul; 32(7):599-606. PubMed ID: 15246155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
    Luznik L; Jalla S; Engstrom LW; Iannone R; Fuchs EJ
    Blood; 2001 Dec; 98(12):3456-64. PubMed ID: 11719388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
    Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
    J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of Nonmyeloablative Allogeneic Hematopoietic Stem Cells for 14 Case of Severe Acquired Aplastic Anemia].
    Wang SF; Huang YJ; Yu CL; Sun QY; Qiao JH; Hu KX; Zuo HL; Dong Z; Liu ZQ; Wang Y; Huang XM; Ai HS; Guo M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1097-102. PubMed ID: 26314453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.
    Ueno NT; Cheng YC; Rondón G; Tannir NM; Gajewski JL; Couriel DR; Hosing C; de Lima MJ; Anderlini P; Khouri IF; Booser DJ; Hortobagyi GN; Pagliaro LC; Jonasch E; Giralt SA; Champlin RE
    Blood; 2003 Nov; 102(10):3829-36. PubMed ID: 12881308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.
    Warren EH; Greenberg PD; Riddell SR
    Blood; 1998 Mar; 91(6):2197-207. PubMed ID: 9490709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
    Rodriguez R; Parker P; Nademanee A; Smith D; O'Donnell MR; Stein A; Snyder DS; Fung HC; Krishnan AY; Popplewell L; Cohen S; Somlo G; Angelopoulou M; Al-Kadhimi Z; Falk PM; Spielberger R; Kogut N; Sahebi F; Senitzer D; Slovak M; Schriber J; Forman SJ
    Bone Marrow Transplant; 2004 Jun; 33(11):1123-9. PubMed ID: 15064696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Rowley SD; Goldberg SL; Pecora AL; Hsu JS; Brecher BA; Butrin L; Kobbe K; McKiernan P; Preti R
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):784-93. PubMed ID: 15505609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.